BioVie Inc. (BIVIW) स्टॉक विश्लेषण

कंपनी का अवलोकन

BioVie Inc. is a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for neurological, neurodegenerative disorders, and advanced liver disease within the United States. The company operates primarily in the healthcare sector, specifically focusing on clinical-stage biopharmaceutical research, though specific industry classifications are not currently disclosed in available records. The organization employs a workforce of 13 individuals, reflecting a lean operational structure typical of early-stage biotechnology firms. Its market capitalization and annual revenue figures are listed as unavailable, which indicates that the company is likely in a pre-revenue or pre-profitability phase where traditional valuation metrics based on earnings or sales multiples are not yet applicable. This lack of reported revenue and market cap data suggests the company is currently allocating resources toward research and development rather than commercial scaling, a common characteristic for firms in the clinical-stage phase of drug discovery.

वित्तीय स्वास्थ्य

The company reports a net income of negative 17,478,136 dollars and an EBITDA of negative 17,968,812 dollars over the trailing twelve months, while revenue data is unavailable. The significant gap between revenue (which is not reported) and net income reveals that the company is operating at a loss, likely due to high R&D expenditures and clinical trial costs that are not being offset by commercial sales. Free cash flow stands at negative 8,277,755 dollars, indicating that the company's cash outflows for operations and capital expenditures exceed its cash inflows, necessitating external financing or cash reserves to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated sufficient profitable sales to establish positive operational efficiency or profitability. On the balance sheet, the company holds 20.54 million dollars in cash against 314,915 dollars in debt, resulting in a debt-to-equity ratio of 1.64. Despite the debt-to-equity ratio appearing elevated, the substantial cash reserve relative to debt suggests the balance sheet is currently conservative regarding immediate solvency risks. The current ratio is 7.25, which signifies a very strong ability to meet short-term obligations with current assets, providing ample liquidity for ongoing research activities. Return on Equity is -80.7% and Return on Assets is -47.2%, metrics that reveal that management has not yet generated returns on the capital invested in the business, a typical scenario for clinical-stage companies before product approval.

मूल्यांकन आकलन

Trailing P/E and forward P/E ratios are both unavailable, which implies that there are no expected earnings trajectories to evaluate using traditional price-to-earnings multiples due to the absence of positive net income. The price-to-book ratio is 0.08, indicating that the market values the company's equity at less than one-eighth of its book value, suggesting the market prices the firm below its accounting net asset value. Price-to-sales ratio and EV/EBITDA metrics are also unavailable, meaning alternative valuation methods that rely on revenue or operating leverage cannot currently be applied to assess the firm's intrinsic value. The stock has traded between a 52-week low of 0.20 dollars and a 52-week high of 0.31 dollars. Without a specific current share price provided in the facts, the exact percentage distance from the high or low cannot be calculated, but the trading range demonstrates volatility within a narrow band typical for small-cap biopharmaceutical stocks. The beta value is 0.56, which indicates that the stock's price volatility is approximately 44% lower than the broader market, suggesting the asset is less sensitive to general market movements.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both unavailable, preventing an analysis of whether earnings are growing faster or slower than revenue. Since the company does not pay dividends, the dividend yield and payout ratio are unavailable, and the firm reinvests its limited earnings and cash reserves back into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a focus on capital appreciation through potential future drug approvals rather than current cash flow generation or dividend income. The unavailability of growth rates and the absence of dividend payments define the company's financial strategy as one of aggressive reinvestment in clinical trials to achieve future commercialization milestones.